14 July 2020
BEUC applauds the EU Commission for achieving that pharma company Aspen is now ready to lower the price of certain anti-cancer drugs by on average 73% in Europe for the next 10 years. Today’s commitments come after the EU Commission opened an antitrust investigation in May 2017 into whether Aspen breached EU antitrust rules’ ban on dominant companies imposing unfair prices.
08 April 2020
The current pandemic is a stress test for our health care systems and sky-high medicines prices are one of the problems that need solving. As vaccines, testing kits and treatments are urgently needed to tackle COVID-19, BEUC urges the EU to ensure that public funding into treatment research results in medicines that are affordable to all. Experience shows that public investment in medicines research − such as cancer drugs − does not always ensure fair prices.
13 March 2020
The COVID-19 outbreak has resulted in major disruption to people’s daily lives, travels and finances. Consumer groups from the BEUC network are advising people in their countries what to do. Please find below a list of advice for your country, in addition to the recommendations of the World Health Organization (WHO) and your governments.
Our work areas
As consumers are faced with a growing amount of information from different sources, we advocate for high quality and non-promotional information about health products.
The ageing of the population, rising healthcare costs and the economic crisis are challenging the sustainability of healthcare systems and consumers’ access to treatments.
Health scandals such as the weight-loss drug Mediator and the faulty PIP breast implants keep undermining consumers’ confidence in the safety of available health products and their oversight by the competent authorities.
- Ensure consumers have access to high quality healthcare in all EU Member States
- Guarantee consumers benefit from safe and innovative treatments
- Allow consumers to make informed choices regarding their health